Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tango Therapeutics, Inc. (TNGX) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology company. Tango Therapeutics files a range of documents with the U.S. Securities and Exchange Commission that describe its financial condition, capital markets activities, and key corporate events, complementing its focus on discovering and developing precision cancer medicines using synthetic lethality.
Through Forms 8-K, Tango Therapeutics reports material events such as equity financings, at-the-market offering programs, and private placements, including underwriting agreements for registered offerings of common stock and pre-funded warrants, and securities purchase agreements for PIPE transactions. These filings often explain the intended use of proceeds, which the company has stated includes advancing its pipeline and supporting working capital and general corporate purposes, as well as expectations for its cash runway.
Other 8-K filings furnish press releases that summarize quarterly financial results and provide business highlights, including updates on clinical trials for vopimetostat (TNG462), TNG456, and TNG260. Filings also document corporate governance developments, such as leadership transitions, board appointments, and executive departures. Registration statements and prospectus supplements referenced in these filings outline the structure and terms of Tango Therapeutics’ capital raising activities.
On Stock Titan, users can review Tango Therapeutics’ SEC filings alongside AI-powered summaries that help explain the significance of each document. This includes quick insights into quarterly earnings releases (often furnished on Form 8-K), material financing agreements, at-the-market sales agreements, and other key disclosures. The filings page supports investors who want to understand how Tango Therapeutics funds its clinical-stage oncology programs, manages its capital structure, and reports material corporate events under SEC requirements.
Tango Therapeutics, Inc. (TNGX) filed a Form 144 reporting a proposed sale of 642,906 common shares through broker BTIG, LLC, with an aggregate market value of $4,461,767 and an indicated approximate sale date of 09/05/2025. The filing shows the shares were originally acquired as a pre-IPO investment on 03/23/2017 and payment for that acquisition was by wire. The filing also discloses sales by Third Rock Ventures IV, L.P. totaling 1,402,194 shares in August 2025 for combined gross proceeds of $9,425,118. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Third Rock Ventures-related entities reported a sale of Tango Therapeutics (TNGX) shares. On 08/22/2025, Third Rock Ventures IV, L.P. sold 302,194 shares of common stock in multiple transactions at a weighted average price of $7.00–$7.05 per share. After the sale, the reporting person holds 15,456,881 shares, held indirectly through the fund and its GP structure. The filing lists Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC as reporting persons and includes a footnote clarifying the weighted-average price range and the entities' disclaimers of beneficial ownership except to the extent of pecuniary interest.
Tango Therapeutics, Inc. reported that Douglas Barry has resigned from his roles as Chief Legal and Compliance Officer and Corporate Secretary. He notified the board of directors on August 21, 2025, and his resignation will be effective as of September 12, 2025. The company states that he is leaving to pursue another opportunity.
Tango Therapeutics, Inc. (TNGX) filed a Form 144 reporting a proposed sale of 302,194 common shares through BTIG, LLC with an aggregate market value of $2,085,138.60, intended to be sold on 08/22/2025 on the NASDAQ GM. The filer acquired these shares on 03/23/2017 as a pre-IPO investment from Tango Therapeutics, Inc., and payment for that acquisition was by wire. The filing also discloses a related sale in the past three months: Third Rock Ventures IV, L.P. sold 1,100,000 common shares on 08/19/2025 for gross proceeds of $7,712,760.00. The notice includes the filer’s standard representation that no undisclosed material adverse information is known.
Third Rock Ventures entities reported a sale of Tango Therapeutics (TNGX) common stock on 08/19/2025. The filing states 1,100,000 shares were sold at a weighted-average price of $7.0116 per share (prices ranged $7.00–$7.12). After the sale, Third Rock Ventures IV, L.P. is reported to beneficially own 15,759,075 shares, held indirectly through its GP entities. The report is filed by multiple related reporting persons and includes the standard disclaimers that the GP entities disclaim beneficial ownership except for any pecuniary interest.
Tango Therapeutics, Inc. (TNGX) filing a Form 144 notifies of a proposed sale of 1,100,000 common shares — an aggregate market value of $7,656,000.00 — to be executed through BTIG, LLC on the NASDAQ GM with an approximate sale date of 08/19/2025. The shares were acquired as a Pre-IPO investment from Tango Therapeutics Inc. on 03/23/2017, paid via wire. The filer reports no securities sold in the past three months and certifies no undisclosed material adverse information. The notice follows Rule 144 disclosure requirements for proposed insider or affiliate sales.
Tango Therapeutics disclosed that Woodline Partners LP, acting as investment adviser to Woodline Master Fund LP, beneficially owns 6,029,906 shares of the company's common stock. That holding represents approximately 5.6% of the class based on an aggregate of 108,394,190 shares outstanding as reported in the company's quarterly report. The reporting party states it has sole voting and sole dispositive power over those shares.
The filing notes the shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer. The report identifies Woodline Partners as a Delaware limited partnership and names the Woodline Fund as the direct holder of the reported shares.
Farallon-affiliated funds and related individuals filed an amended Schedule 13G reporting material passive holdings of Tango Therapeutics common stock. Farallon Partners, L.L.C. is shown as beneficial owner of 8,798,334 shares (8.1%) and the Farallon Individual Reporting Persons are shown with a collective 9,157,000 shares (8.4%). Several underlying Farallon funds report individual holdings, including Farallon Capital Offshore Investors II with 3,754,671 shares (3.5%) and Farallon Capital Institutional Partners with 2,023,027 shares (1.9%).
The filing states the shares are held directly by the named funds and that the general partner entities and listed individuals could be deemed beneficial owners while disavowing beneficial ownership of those shares. The Schedule is a passive disclosure of ownership and includes a certification that the securities were not acquired to effect a change of control.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 5,905,349 shares of Tango Therapeutics common stock, equal to 5.45% of the company’s outstanding shares based on an 108,394,190 share count used in the filing. The reported position shows shared voting and dispositive power of 5,905,349 shares and no sole voting or dispositive power.
The filing is submitted on Schedule 13G and states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.